Artal Group S.A. - Q1 2020 holdings

Add to watchlist

$2.37 Billion is the total value of Artal Group S.A.'s 105 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 67.9% .

All

			Value		Shares		↓ Weighting
BNTX	Sell	BIONTECH SEsponsored ads	$130,123,000	+46.1%	2,228,130	-15.2%	5.50%	+59.9%
MRNA	Sell	MODERNA INC	$89,850,000	-0.3%	3,000,000	-34.9%	3.80%	+9.1%
BABA	Sell	ALIBABA GROUP HLDG LTDsponsored ads	$77,792,000	-18.5%	400,000	-11.1%	3.29%	-10.8%
AVTR	Sell	AVANTOR INC	$56,205,000	-34.8%	4,500,000	-5.3%	2.38%	-28.7%
AGIO	Sell	AGIOS PHARMACEUTICALS INC	$14,192,000	-50.5%	400,000	-33.3%	0.60%	-45.8%
UBER	Sell	UBER TECHNOLOGIES INC	$11,168,000	-24.9%	400,000	-20.0%	0.47%	-17.8%
HOOK	Sell	HOOKIPA PHARMA INC	$6,569,000	-46.6%	796,259	-20.8%	0.28%	-41.5%
TBIO	Sell	TRANSLATE BIO INC	$5,982,000	+13.1%	600,000	-7.7%	0.25%	+24.0%
CLVS	Sell	CLOVIS ONCOLOGY INCcall	$3,180,000	-59.3%	500,000	-33.3%	0.13%	-55.6%
TWST	Exit	TWIST BIOSCIENCE CORP	$0	–	-100,000	-100.0%	-0.08%	–
VKTX	Exit	VIKING THERAPEUTICS INC	$0	–	-350,000	-100.0%	-0.11%	–
NTLA	Exit	INTELLIA THERAPEUTICS INC	$0	–	-199,700	-100.0%	-0.11%	–
SGMO	Exit	SANGAMO THERAPEUTICS INC	$0	–	-405,000	-100.0%	-0.13%	–
DOYU	Exit	DOUYU INTERNATIONAL HLDNGS Lsponsored ads	$0	–	-400,000	-100.0%	-0.13%	–
REAL	Exit	THE REALREAL INC	$0	–	-200,000	-100.0%	-0.15%	–
KRTX	Exit	KARUNA THERAPEUTICS INC	$0	–	-50,000	-100.0%	-0.15%	–
STML	Exit	STEMLINE THERAPEUTICS INC	$0	–	-360,000	-100.0%	-0.15%	–
FATE	Exit	FATE THERAPEUTICS INCcall	$0	–	-200,000	-100.0%	-0.15%	–
LGFA	Exit	LIONS GATE ENTMNT CORPcall	$0	–	-500,000	-100.0%	-0.21%	–
IGMS	Exit	IGM BIOSCIENCES INC	$0	–	-150,000	-100.0%	-0.22%	–
NIO	Exit	NIO INCcall	$0	–	-1,750,000	-100.0%	-0.27%	–
INCY	Exit	INCYTE CORPcall	$0	–	-100,000	-100.0%	-0.34%	–
MRNA	Exit	MODERNA INCcall	$0	–	-500,000	-100.0%	-0.38%	–
RETA	Exit	REATA PHARMACEUTICALS INCcl a	$0	–	-50,000	-100.0%	-0.40%	–
NKTR	Exit	NEKTAR THERAPEUTICScall	$0	–	-500,000	-100.0%	-0.42%	–
DRNA	Exit	DICERNA PHARMACEUTICALS INC	$0	–	-500,000	-100.0%	-0.43%	–
XNCR	Exit	XENCOR INC	$0	–	-550,000	-100.0%	-0.73%	–
MS	Exit	MORGAN STANLEYcall	$0	–	-2,000,000	-100.0%	-3.95%	–

Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR filed 2020-05-14

Signatures

The EDGAR filing(s) were signed by:

Anne Goffard — Authorized Person

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
AGENUS INC	42	Q3 2023	1.9%
IRONWOOD PHARMACEUTICALS INC	42	Q3 2023	0.3%
ALNYLAM PHARMACEUTICALS INC	37	Q3 2023	5.1%
LEXICON PHARMACEUTICALS INC	34	Q3 2023	20.6%
AMICUS THERAPEUTICS INC	30	Q3 2023	2.7%
BEIGENE LTD	28	Q3 2023	7.4%
BK OF AMERICA CORP	28	Q1 2021	4.3%
SAGE THERAPEUTICS INC	28	Q2 2023	1.9%
AGIOS PHARMACEUTICALS INC	28	Q2 2020	1.1%
NEKTAR THERAPEUTICS	27	Q2 2020	1.3%

View Artal Group S.A.'s complete holdings history.

Latest significant ownerships (13-D/G)

Artal Group S.A. Q1 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
WEIGHT WATCHERS INTERNATIONAL INC	February 13, 2015	29,443,300	51.9%

View Artal Group S.A.'s complete significant-ownership history.

Latest filings

Type	Filed
13F-HR/A	2024-05-17
4	2024-05-14
13F-HR	2024-05-13
4	2024-03-25
4	2024-03-13
4	2024-02-29
13F-HR	2024-02-09
13F-HR	2023-11-13
4	2023-10-16
13F-HR	2023-08-11

View Artal Group S.A.'s complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

The reported total value is incorrect (2366281000.0 != 2366280000.0)

Export Artal Group S.A.'s holdings